Cytomegalovirus viremia, mortality, and end-organ disease among patients with AIDS receiving potent antiretroviral therapies

Journal of Acquired Immune Deficiency Syndromes

Volumn 38, Issue 5, 2005, Pages 538-544

  Wohl, David A ^a   Zeng, Donglin ^b   Stewart, Paul ^b   Glomb, Nicolas ^a   Alcorn, Timothy ^c   Jones, Suzanne ^a   Handy, Jean ^a   Fiscus, Susan ^a   Weinberg, Adriana ^d   Gowda, Deepthiman ^e   Van Der Horst, Charles ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

^c Esoterix Inc   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

AIDS; Antiretroviral therapy; Cytomegalovirus; Viremia

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; VIRUS DNA; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; COHORT ANALYSIS; CYTOMEGALOVIRUS INFECTION; DEATH; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATION; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RETINITIS; SYMPTOM; UNITED STATES; UNIVERSITY HOSPITAL; VIREMIA; VIRUS DETECTION; VIRUS LOAD;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CONTINENTAL POPULATION GROUPS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; ETHNIC GROUPS; FOLLOW-UP STUDIES; HIV; HIV INFECTIONS; HUMANS; MIDDLE AGED; STUDENTS; SURVIVAL ANALYSIS; TIME FACTORS; VIRAL LOAD; VIREMIA;

EID: 20244370518     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000155204.96973.c3     Document Type: Article

References (16)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:85360.
2. Mocroft A, Devereux H, Kinloch-de-Loes S, et al. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. AIDS. 2000;14:1545-1552.
3. Jabs D, Bartlett JG. AIDS and ophthalmology: a period of transition. Am J Ophthalmol. 1997;124:227-233.
4. Baril L, Jouan M, Agher RA, et al. Impact of highly active antiretroviral therapy on onset of Mycobacterium avium complex infection and cytomegalovirus disease in patients with AIDS. AIDS. 2000;14:2593-2596.
5. Holtzer CD, Jacobson MA, Hadley WK, et al. Decline in the rate of specific opportunistic infections at San Francisco General Hospital, 1994-1997. AIDS. 1998;12:1931-1933.
6. Jacobson MA, Stanley H, Holtzer C, et al. Natural history and outcome of new AIDS-related cytomegalovirus retinitis diagnosed in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30:231-233.
7. Kempen JH, Jabs DA, Wilson LA, et al. Mortality risk for patients with cytomegalovirus retinitis and acquired immune deficiency syndrome. Clin Infect Dis. 2003;37:1365-1373.
8. Spector SA, Hsia K, Crager M, et al. Plasma cytomegalovirus DNA load is an independent predictor of CMV disease and survival in advanced AIDS. J Virol. 1999;73:7027-7030.
9. Bowen EF, Sabin CA, Wilson P, et al. Cytomegalovirus viremia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease. AIDS. 1997;11:889-893.
10. Walmsey S, O'Rourke K, Mortimer C, et al. Predictive value of cytomegalovirus antigenemia and digene hybrid capture DNA assays for CMV disease in human immunodeficiency virus-infected patients. Clin Infect Dis. 1998;27:573-581.
11. Caliendo AM, Schuurman R, Yen-Liberman B, et al. Comparison of quantitative and qualitative PCR assays for cytomegalovirus DNA in plasma. J Clin Microbiol. 2001;39:1334-1338.
12. Casado JL, Arrizabalaga J, Montes M, et al. Incidence and risk factors for developing cytomegalovirus retinitis in HIV-infected patients receiving protease inhibitor therapy. AIDS. 1999;13:1497-1502.
13. Deayton JR, Sabin CA, Johnson MA, et al. Importance of cytomegalovirus viremia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. Lancet. 2004;363:2116-2121.
14. Erice A, Tierney C, Hirsch M, et al. Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360). Clin Infect Dis. 2003;37:567-578.
15. Cox DR, Oakes D. Analysis of Survival Data. London: Chapman and Hall; 1984.
16. Salmon-Ceron D, Mazeron M, Chaput S, et al. Plasma cytomegalovirus DNA, pp65 antigenemia, and a low CD4+ cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy. AIDS. 2000;14:1041-1049.